Love Employee/iStock via Getty Images
- Privately held Rondo Therapeutics has inked an agreement with Eli Lilly (NYSE:LLY) to develop T cell-engaging bispecific antibodies for the treatment of solid tumors.
- The arrangement will utilize Rondo’s proprietary CD28 co-stimulatory platform.
- While specific financial terms weren’t disclosed, Rondo will receive an upfront payment and is eligible for milestone payments as well as tiered royalties on sales from any potential treatments.
- Lilly has also been granted exclusive worldwide rights to develop a CD28 therapy for a defined cancer target.
- Rondo said its platform “delivers bispecific antibody therapeutics tailored to specific tumor targets, indications, and treatment regimens, offering a transformative alternative to traditional ‘one size fits all’ strategies.”